MedTrace Logo

A Trial of HR18034 for Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy.

NCT05376904 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2023-03-20

No results posted yet for this study

Summary

The study is being conducted to evaluate the efficacy, and safety of HR18034 for postoperative analgesia in subjects undergoing hemorrhoidectomy. To explore the reasonable dosage of HR18034 for postoperative analgesia in subjects undergoing hemorrhoidectomy.

Conditions

  • Postsurgical Pain Management

Interventions

DRUG

HR18034

HR18034 low dose

DRUG

HR18034

HR18034 midium dose

DRUG

HR18034

HR18034 high dose

DRUG

ropivacaine HCl.

ropivacaine HCl.

Sponsors & Collaborators

  • Shanghai Hengrui Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-13
Primary Completion
2022-10-05
Completion
2022-10-05

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05376904 on ClinicalTrials.gov